Company Description
PAREXEL International excels in biopharmaceuticals. A top contract research organization (CRO), the firm counts among its clients some of the world's...
Key PAREXEL Financials
| Company Type | Public - NASDAQ (GS): PRXL Main Headquarters |
|---|---|
| Fiscal Year-End | June |
| 2007 Sales (mil.) | $918.1 |
| 2006 Employees | 5,600 |
More PAREXEL Financials (11 pages)
Latest PAREXEL Jobs jobs by Indeed
Rankings
- S&P 600
Competition
Competitive Landscape for Healthcare
Although a large majority of hospitals are operated by nonprofits, most doctor offices, nursing homes, insurers, and manufacturers of medical products are for-profit entities. The industry is one of...
Read more about PAREXEL's competition across multiple industries
Top PAREXEL Competitors
Sponsored Links
The Business DirectoryTrading Toolbox
PAREXEL Executives sponsored by genius.com
| Title | Name & Bio | Contact |
|---|---|---|
| Chairman and CEO | Josef H. von Rickenbach | Network | E-mail |
| EVP, Corporate Quality, Administration, and PAREXEL Consulting and Marketing Services | Michael E. Woehler | Network | E-mail |
| SVP and CFO | James F. Winschel Jr. | Network | E-mail |
| Are You Listed On Hoover's? | ||
|---|---|---|
| Hoover's subscribers also get access to information on people who have self-listed with this company. Subscribers also have the option to add themselves to this company record. |
Tools from our advertising partners:
Current PAREXEL News
- Quintiles won't bid on ClinPhone: Drug tester, seller focuses on growth [News & Observer (Raleigh, NC)] (01 Jul 2008 04:00:00 EDT)
- PAREXEL Enhances Early Phase Clinical Development Offering for Central Nervous System Studies [Pain & Central Nervous System Week] (30 Jun 2008 00:01:00 EDT)
- Briefing.com: Hourly In Play (R) - 23:00 ET [Briefing.com] (25 Jun 2008 23:00:00 EDT)
Latest Industry Video
-
Rx For Cheap Drugs (4:04)
07/23/07 5:20PM ET - Miller Tabak & Co. Pharmaceuticals Analyst Les Fundleyder and Bain & Company Partner Tim Van Biesen discuss patent expirations affecting U.S. drug costs.